STERIS Short Interest Retreats Ahead of Tuesday Print

STE is the least crowded name among its closest medical device peers heading into Tuesday's results, with short interest having fallen sharply while several correlated stocks carry heavier bearish positioning.

Short sellers have been retreating from STERIS at an unusual pace. Short interest dropped 31% in the past week to roughly 1.97% of the free float, a decline running 2.1 standard deviations below the company's typical weekly move. That compares with peers such as MMSI and SYK, both of which fell more than 6% on Friday alone, suggesting more active repositioning in those names. The borrow market for STERIS reflects this light positioning: availability is extremely loose at 3,942%, meaning there are nearly 40 shares available to lend for every one currently borrowed, well above the 52-week low availability of 1,142%. Cost to borrow ticked up 73% in the past week to 0.62%, but from a very low base, and the absolute level still points to easy borrow conditions. Options positioning is modestly more cautious, with the put/call ratio at 0.60, above its 20-day average of 0.47, though well within normal range on a z-score basis.

The analyst community holds a hold consensus, but the coverage skews constructively on targets. UBS and Piper Sandler both carry positive ratings with targets in the $270 to $275 range, against a current price of $227. The bull case centres on organic revenue momentum: total revenue grew 5% year over year in the most recent quarter, with the EBIT margin up 110 basis points and EPS up 14%, aided by the dental segment divestiture reducing interest costs. Bears point in the opposite direction at the product mix: capital equipment sales fell around 16% year over year, service revenues dropped 21%, and the backlog shrank by $66 million versus the prior quarter. Those are not peripheral segments, they are the growth engine of the sterilization workflow business, and their deterioration raises a clear question about whether consumables momentum can offset the drag.

The stock trades at a trailing PE near 18.7x, up roughly 1.3 points over the past month after a 7.8% monthly rally, yet still below the mean analyst target by around 15%. Retail attention is running elevated, with STERIS's Wikipedia view z-score reaching 2.0 above its own 90-day baseline as of late October, though the alt data layer carries no measured lead against financial results, so that signal speaks only to interest, not direction. Among top holders, Wellington Management added 629,532 shares through August, the largest institutional move in the register. No 13D activist appears on the SEC filings, and the activist register carries only passive Schedule 13G filers. The insider record over the past 90 days shows a net sale of around 4,058 shares worth roughly $957,000 by a director, though the companion option exercise suggests the transaction was largely mechanical rather than a discretionary reduction in exposure.

The print on Tuesday will test whether the capital equipment backlog stabilisation management alluded to in prior commentary has begun to convert into order intake, and whether organic growth in the remaining segments can move the margin trajectory without it.